For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
After finishing at $14.96 in the prior trading day, Adaptive Biotechnologies Corp (NASDAQ: ADPT) closed at $14.56, down -2.67%. In other words, the price has decreased by -$2.67 from its previous closing price. On the day, 2.68 million shares were traded. ADPT stock price reached its highest trading level at $15.26 during the session, while it also had its lowest trading level at $14.52.
Ratios:
Our goal is to gain a better understanding of ADPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.75 and its Current Ratio is at 2.84. In the meantime, Its Debt-to-Equity ratio is 1.21 whereas as Long-Term Debt/Eq ratio is at 1.14.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Guggenheim on September 30, 2025, initiated with a Buy rating and assigned the stock a target price of $20.
On June 18, 2025, Craig Hallum started tracking the stock assigning a Buy rating and target price of $15.
Goldman Upgraded its Neutral to Buy on March 21, 2025, while the target price for the stock was maintained at $9.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 16 ’25 when PISKEL KYLE sold 1,929 shares for $8.89 per share. The transaction valued at 17,149 led to the insider holds 277,396 shares of the business.
ROBINS HARLAN S sold 68,412 shares of ADPT for $502,828 on May 01 ’25. The Chief Scientific Officer now owns 1,279,524 shares after completing the transaction at $7.35 per share. On May 01 ’25, another insider, Harlan Robins, who serves as the Officer of the company, bought 68,412 shares for $7.36 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ADPT now has a Market Capitalization of 2217108224 and an Enterprise Value of 2236989184. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.80 while its Price-to-Book (P/B) ratio in mrq is 12.33. Its current Enterprise Value per Revenue stands at 10.901 whereas that against EBITDA is -21.753.
Stock Price History:
The Beta on a monthly basis for ADPT is 2.07, which has changed by 1.9565217 over the last 52 weeks, in comparison to a change of 0.17342639 over the same period for the S&P500. Over the past 52 weeks, ADPT has reached a high of $15.04, while it has fallen to a 52-week low of $4.27. The 50-Day Moving Average of the stock is 16.39%, while the 200-Day Moving Average is calculated to be 53.23%.
Shares Statistics:
The stock has traded on average 1.96M shares per day over the past 3-months and 2144830 shares per day over the last 10 days, according to various share statistics. A total of 152.23M shares are outstanding, with a floating share count of 146.96M. Insiders hold about 3.49% of the company’s shares, while institutions hold 95.06% stake in the company. Shares short for ADPT as of 1757894400 were 9344814 with a Short Ratio of 4.78, compared to 1755216000 on 8945230. Therefore, it implies a Short% of Shares Outstanding of 9344814 and a Short% of Float of 7.8600004000000006.
Earnings Estimates
Its stock is currently analyzed by 7.0 different market analysts. The consensus estimate for the next quarter is -$0.17, with high estimates of -$0.1 and low estimates of -$0.21.
Analysts are recommending an EPS of between -$0.56 and -$0.8 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.57, with 7.0 analysts recommending between -$0.42 and -$0.66.
Revenue Estimates
7 analysts predict $58.76M in revenue for. The current quarter. It ranges from a high estimate of $71.8M to a low estimate of $54.23M. As of. The current estimate, Adaptive Biotechnologies Corp’s year-ago sales were $46.44MFor the next quarter, 7 analysts are estimating revenue of $62.95M. There is a high estimate of $73M for the next quarter, whereas the lowest estimate is $57.6M.
A total of 8 analysts have provided revenue estimates for ADPT’s current fiscal year. The highest revenue estimate was $256.09M, while the lowest revenue estimate was $224.1M, resulting in an average revenue estimate of $232.69M. In the same quarter a year ago, actual revenue was $178.96MBased on 8 analysts’ estimates, the company’s revenue will be $270.63M in the next fiscal year. The high estimate is $279.6M and the low estimate is $252.48M.
